Patents Examined by Kortney L Klinkel
  • Patent number: 11564922
    Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: January 31, 2023
    Assignee: AbbVie Inc.
    Inventors: Aileen L. Pangan, Roopal B. Thakkar, Steven Jungerwirth, Ana Paula Machado De Lacerda, Anne M. Robinson, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Wen Zhou
  • Patent number: 11559482
    Abstract: The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: January 24, 2023
    Assignee: Ascendis Pharma A/S
    Inventors: Harald Rau, Ulrich Hersel, Mathias Krusch, Dirk Vetter, Tobias Voigt
  • Patent number: 11555009
    Abstract: The invention provides 2-(substituted phenylhetero) aromatic formate FTO inhibitors, a preparation method thereof, and applications thereof. Specifically, disclosed in the present invention are a 2-(substituted phenylhetero) aromatic formate compound represented by the following formula (I), and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, which can be used as an FTO targeting inhibitor for treating diseases associated with FTO targets, including obesity, metabolic syndrome (MS), type 2 diabetes (T2D), Alzheimer's diseases, and cancers such as breast cancers, small-cell lung cancers, human bone marrow rhabdomyosarcoma, pancreatic cancer, malignant glioblastoma and the like.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: January 17, 2023
    Inventors: Caiguang Yang, Yue Huang, Ze Dong, Tao Zhang, Hongjiao Xu
  • Patent number: 11553712
    Abstract: The disclosure relates to uses, methods and compositions for the inactivation of pathogens in biological compositions, using a glycol as a pathogen inactivating agent.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: January 17, 2023
    Assignee: Laboratoire Français du Fractionnement et des Biotechnologies
    Inventor: Sami Chtourou
  • Patent number: 11548860
    Abstract: The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compounds have the formula: [Chem.
    Type: Grant
    Filed: October 22, 2016
    Date of Patent: January 10, 2023
    Inventor: Njabulo Joyfull Gumede
  • Patent number: 11542247
    Abstract: The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: January 3, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Diego Fernando Domenico Broggini, Filip Albert C Cuyckens, Steven Anna Hostyn, Russell Mark Jones, Olivier Alexis Georges Querolle, Wim Vermeulen
  • Patent number: 11534437
    Abstract: The present disclosure is directed to method of treatment for treating or ameliorating various conditions caused by radiation exposure such as RIGS, enteritis, mucositis, e.g., oral mucositis, and proctitis by the administration of compound 512, or an analog thereof.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: December 27, 2022
    Assignee: BCN Biosciences L.L.C.
    Inventor: Andrew J. Norris
  • Patent number: 11524930
    Abstract: The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, F or OH; R2 is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R3 is H, F, OH or CH2Ph; R4 is H, F or OH; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH, or 6) C(O)—C(O)OH; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: December 13, 2022
    Inventors: Boulos Zacharie, Shaun Abbott, Lyne Gagnon, Pierre Laurin, Brigitte Grouix
  • Patent number: 11517552
    Abstract: A method for treating psoriasis including the steps of applying an isothiocyanate functional surfactant to an area affected by psoriasis, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: December 6, 2022
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 11504370
    Abstract: Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: November 22, 2022
    Inventors: Patrice A. Lee, Shannon L. Winski, Kevin Koch
  • Patent number: 11497720
    Abstract: This invention pertains to an anti-microbial, in particular anti-bacterial, more particularly against Gram negative bacteria, and/or anti-fungal composition comprising as active blend trans-cinnamaldehyde and a potentiating agent. In particular this composition is intended for preventing and/or treating microbial infection in an animal.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: November 15, 2022
    Assignee: SEPTEOS
    Inventor: Nicolas Tesse
  • Patent number: 11478481
    Abstract: The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives represented by formula (IA) and (IB), processes for preparing the alcohol derivatives and their use in preparing pharmaceuticals.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: October 25, 2022
    Inventors: Jayaraman V. Raman, Swaroop K. Vakkalanka
  • Patent number: 11464785
    Abstract: This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: October 11, 2022
    Inventors: Gregory A. Demopulos, George A. Gaitanaris, Roberto Ciccocioppo
  • Patent number: 11458135
    Abstract: The present invention relates to pure 5-HT6 receptor antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitors and their use in the treatment of cognitive disorders. The invention further provides the pharmaceutical composition containing the said combination.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: October 4, 2022
    Assignee: Suven Life Sciences Limited
    Inventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Ramasastri Kambhampati, Venkateswarlu Jasti
  • Patent number: 11452701
    Abstract: In one aspect, the present invention features an emulsion composition including (i) at least 3%, by weight, of a nonsteroidal anti-inflammatory drug; (ii) at least 15%, by weight, of isopropyl myristate; (iii) at least 25%, by weight, of water; and (iv) one or more emulsifiers; wherein the formulation is substantially free of C1-C4 alcohols.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: September 27, 2022
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Saumitra Bagchi, Donald Hasenmayer
  • Patent number: 11439643
    Abstract: The present invention relates to compositions and methods for treating lymphoma in a subject in need thereof, said methods comprising administering to the patient in need thereof a therapeutically effective amount of a combination of belinostat and pralatrexate, wherein said therapeutically effective amount results in a synergistic antiproliferative effect on cancer cell growth.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: September 13, 2022
    Assignee: Acrotech Biopharma Inc.
    Inventor: Guru Reddy
  • Patent number: 11261154
    Abstract: A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: March 1, 2022
    Inventors: Shoji Nojima, Kenji Sasaki, Tohru Kambe, Takashi Konemura, Yoshikazu Goto
  • Patent number: 11253506
    Abstract: The present invention includes compounds, compositions and methods for treating and/or preventing chlorine inhalation toxicity and/or injury in a subject subjected to chlorine inhalation.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: February 22, 2022
    Inventor: Livia A. Veress
  • Patent number: 11234377
    Abstract: Pesticide compositions containing an adjuvant which contains, based on 100 parts by weight of the adjuvant, (a) greater than about 50 parts by weight of at least one alkyl fatty acid ester, (b) from about 2 parts by weight to less than about 5 parts by weight of a surfactant comprising: (b)(i) one or more anionic surfactants selected from sulfonic acids, sulfonic acid esters, alkylsulfosuccinic acid esters, phosphate esters, sulfate esters, and oleoyltaurate salts, or (b)(ii) one or more non-ionic surfactants selected from sorbitan fatty acid esters, aryl alkoxylates, alkoxylated fatty alcohols, alkoxylated fatty acids, alkoxylated triglycerides, alkoxy copolymers, alkylpolyglucosides, alkoxylated fatty amines, and ether amines, or (iii) a mixture (b)(i) and (b)(ii), exhibit improved performance, particularly when sprayed through a flat fan spray nozzle, an air induction spray nozzle, or other spray nozzle and at a pressure of from about 10 pounds per square inch to about 100 pounds per square inch.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: February 1, 2022
    Assignee: SOLVAY USA INC.
    Inventors: Hedieh Modaressi, Joe V. Gednalske, Rajesh Pazhianur, Andrew Douglass, Gregory K. Dahl
  • Patent number: 11229603
    Abstract: This process manufactures a finished medicine that can be used against broad spectrum, Anti-Viral, Anti-Bacterial, Anti-Fungal, and Anti-parasitic disease conditions that attack the human body but not limited to other medical conditions and or other types of treatments use for animals other than humans.
    Type: Grant
    Filed: August 1, 2021
    Date of Patent: January 25, 2022
    Assignee: Reynolds Blue, LLC
    Inventors: Rodney Reynolds, Carmine Russo, Robert Reynolds